Pathogenesis

The etiology of CM is not fully understood, however recent reports of mutations in GNAQ in both syndromic and non-syndromic CMs point to an underlying genetic basis. Another familial form of CM occurring with AVM has been reported in the CM-AVM syndrome.

Cutaneous findings

PWS are pink or red patches that typically grow proportionately with the child’s somatic growth, and persist throughout the patient’s life. They consist of ectatic dermal capillaries and may occur anywhere on the body ( Fig. 22.2A ). PWS may appear to lighten over the first 3–6 months of life, but this should not be taken as a sign of resolution. Rather, this physiologic lightening is due to the decrease in blood hemoglobin concentration corresponding to the change from fetal to adult type hemoglobin ( Fig 22.2B ). Capillary malformations can occur anywhere on the body. They may or may not be associated with overgrowth of the affected area ( Fig. 22.2 ). Port-wine stains on the face tend to follow a dermatomal pattern, respecting the trigeminal nerve V1-V3 distribution or comprising multiple dermatomes ( Fig. 22.3 ). The natural history of port-wine stains over a lifetime is often one of gradual darkening from pink-red to a crimson or deep purple hue. Skin thickening and soft tissue and/or bony hypertrophy may also develop. Eczematous changes can occur in PWS and salmon patches, either with or without treatment. Nodular vascular lesions (pyogenic granulomas) may appear within PWS during childhood or adult life and may require surgical intervention. The association of PWS with pigmentary anomalies such as extensive Mongolian spots, nevus spilus, or nevoid hyperpigmentation is a feature of phakomatosis pigmentovascularis (see further discussion of this entity below, Fig. 22.4 , Table 22.2 ).

(A) Neonate with extensive capillary malformation of the back, upper extremities and left leg; also note infantile hemangioma on the right leg. (B) Same patient aged 1, with subtle overgrowth of the affected limb. Note also the physiologic lightening of the stain with time.

Port-wine stain involving left facial V1 + V2 + V3 and right V3 areas.

The V1 involvement indicates a risk of Sturge–Weber syndrome, which this infant had.

Phakomatosis pigmentovascularis.

(Courtesy of H.P. Makkar.)

Extracutaneous findings

Progressive soft tissue and bony overgrowth may occur during childhood, especially with V2 PWS, and subtle changes are sometimes noted even in the neonatal period. Asymmetric maxillary hypertrophy associated with distortion of the facial features requires multidisciplinary management with orthodontic follow-up and treatment. Some patients require procedures to correct skeletal overgrowth in late childhood. Gingival hypertrophy may also develop. Port-wine stains are also a manifestation of several different syndromes with other extracutaneous features discussed later in the chapter (see ‘Syndromes associated with vascular malformations’, below).

Management

The gradual thickening and nodularity of PWS provide a medical rationale for treatment during infancy and childhood. The flashlamp-pumped pulsed dye laser (PDL) is the gold standard treatment for PWS and poses a very low risk of scarring, even in young infants. It has been used for longer than 15 years and advances such as the development of a cooling system have improved efficacy. Most PDL units have a wavelength of 595 nm. Settings of 0.45–1.5 ms pulse duration, 6–10 J/cm ² fluences, and 7–10 mm spot size along with the coolant system (dynamic cooling device) are used in the majority of cases. Although only 15–20% of PWS clear completely with PDL, the majority of treated lesions lighten significantly. Response to laser treatment varies by area and skin type: outcomes are better on the face and neck, albeit with less improvement in V2 than other facial sites, and are also better in patients with type I–II skin. The extremities do not respond as well. Controversy exists regarding the age at which treatment should begin. Some authors have noted a better therapeutic response with fewer treatments when treatment was initiated in early infancy, but others have found no difference. Treating earlier (in infancy or early childhood) can be helpful in reducing stigmatization and may help prevent thickening of the skin. Treating early in infancy may enable the physician to treat with topical anesthesia, as small infants can be swaddled and held during a brief treatment and local anesthetic can be applied prior to the procedure. In older children with large stains, general anesthesia may be required. In most cases, re-darkening occurs with time and touch-up treatments are often needed in later childhood or teen years.

In treatment-resistant CM, other laser modalities have recently been studied in an attempt to decrease thickness, color, and nodularity. These include the long-pulsed neodymium : yttrium-aluminum-garnet (Nd : YAG) laser, the combined PDL and Nd : YAG laser, and the alexandrite laser.

Other novel therapies show some initial promise, including intense pulsed light (IPL), photodynamic therapy (PDT), and application of topical anti-angiogenic factors (imiquimod and rapamycin) in conjunction with laser ablation.

In cases where there is soft tissue or bony overgrowth, or in syndromic CM, a multidisciplinary approach to management is often necessary. Patients may require orthodontic work, maxillofacial reconstruction or soft tissue debulking. Ideally, follow-up in a multidisciplinary vascular anomalies center is beneficial.

Pathogenesis

VMs are sporadic in the majority of cases, but, familial cases of both VM and (more often) GVM occur. The genetic basis for familial VMs (VMCM syndrome, see below) and GVM are now known. The mutated gene in familial VMCM syndrome maps to chromosome 9p17; and is an activating mutation in the kinase domain of the receptor tyrosine kinase Tie2. Sporadic Tie2 mutations are also found in 50% of sporadic VMs. GVM can be either a sporadic or an autosomal dominant condition, linked to mutations in the glomulin gene (mapping to 1p21–p22). Unlike VMs, far more cases of GVM are familial (approx. 64%).

Cutaneous findings

At birth, the majority of VM are subtle, bluish, ill-defined, compressible plaques or nodules. Rarely, a bulky venous mass is observed in the neonatal period ( Fig. 22.5 ). VMs may be diffuse or localized. Affected skin and mucous membranes are typically blue with normal skin temperature, without a thrill or bruit. Lesions swell when dependent or with crying. In many cases, the blue-hued cutaneous component heralds involvement of deeper structures. Local venous thromboses can lead to the formation of phleboliths, which can be tender when palpated and are visible on radiographs as round calcifications.

Small venous malformation of the finger, with swelling and blue nodularity.

Glomuvenous malformations (GVM; formerly called ‘glomangioma’) may be solitary or multiple, and may be localized or involve a larger territory of skin ( Fig. 22.6 ). They are often bluish to purple, cobblestoned or plaque-like in appearance. During childhood, they typically acquire a deeper blue hue and thicken, and become tender when palpated. Congenital plaque-like GVMs are usually pink at birth, with noticeable thickening and change in color to blue-purple during childhood. These plaque-like GVMs may arise sporadically, or occur as a manifestation of autosomal dominant GVM. Other family members may have smaller, blue vascular lesions scattered over the skin, increasing in number with age.

Extensive glomuvenous malformation on the chest and arms in an infant with + glomulin mutation.

(Courtesy of Ilona Frieden.)

Extracutaneous findings

In addition to skin and mucosal involvement, VM can also involve deeper soft tissues, muscles, joints, and in severe cases, visceral sites such as the abdomen and pelvis. A majority of patients with extensive VMs develop a chronic localized intravascular coagulopathy (LIC), which is distinct from Kasabach–Merritt phenomenon (KMP). VM associated LIC can result in either thrombosis (with pain and phlebolith formation) or bleeding, and persists throughout life. It differs from KMP because the primary process is one of ongoing clotting, with consumption of clotting factors, low fibrinogen and elevated d -dimers, but without the marked thrombocytopenia of KMP. Large and intramuscular VMs are more likely to have associated VM-LIC. Pain is a common complaint either due to phlebolith formation or often in larger extremity lesions. ‘Blue rubber bleb nevus’ syndrome, the association of multiple cutaneous venous malformations with gastrointestinal and other internal lesions, is discussed later in this chapter. Some patients with VM experience worsening of symptoms during puberty or in pregnancy. In contrast to VMs, GVMs are typically localized to the skin and soft tissues without mucosal or intramuscular involvement. GVMs are not associated with LIC.

Diagnosis

The diagnosis is usually established on the basis of clinical features. Imaging modalities including ultrasonography, Doppler, MRI, and CT scans are useful for evaluating the extent of involvement. The finding of associated LIC and specifically elevated d -dimer levels, can help confirm the diagnosis of VM in uncertain cases. Apart from helping to confirm the diagnosis, the decision to image early in infancy depends on whether functional problems are present or early treatments are planned. Many VMs, however, especially larger ones, eventually do require imaging studies, and MRI with contrast is the best study to delineate disease. A number of radiologic classification schema have been proposed and may predict response to treatment, with smaller and more localized lesions being more amenable to sclerotherapy. In individuals with craniofacial VMs, it is advisable to image the brain: developmental venous anomalies (DVA) in the brain are more common in patients with craniofacial VMs than in the general population (25% vs 0.5%). DVAs are uncommon trajectories of the brain’s venous drainage and pose little risk of cerebral hemorrhage, but documenting their presence can help avoid misdiagnosis of a more worrisome condition later in life. Histopathology can also help to confirm the diagnosis when uncertainty is present and/or to distinguish between VM and GVM.

Differential diagnosis

Extensive VMs in a leg or an arm and adjacent trunk must be differentiated from Klippel–Trenaunay and other overgrowth syndromes, as management and prognosis is variable (see Table 22.4 ). Sinus pericranii should be considered in the differential diagnosis of a VM located on the central forehead. This presents as a bluish, nonpulsating mass that is usually congenital and quickly expands when the patient puts their head in a dependent position or with crying. Sinus pericranii represents a direct communication between superficial veins and intracranial venous sinuses through a bony defect. It is best imaged using CT with bone windows.

Course

Venous malformations tend to enlarge and become more symptomatic with time. Their clinical course and complications depend on anatomic location, with differing problems in the craniofacial area, trunk, and limbs. The cheek, lip and tongue are common locations for craniofacial VMs, and there is sometimes deep extension to the temporal and orbital areas. Swelling is noted with dependency and activity. Over time, the VM may progressively distort the facial features and mold the underlying developing bones, which can result in deformities such as an open bite or enlargement of the orbit. Extensive retropharyngeal involvement can result in obstructive sleep apnea, occasionally even in young children. VMs located on the trunk and limbs may involve skin, skeletal muscles, joints, and bones, often causing pain. During infancy and early childhood, the skin component of the VM expands and becomes deep blue. However, the deeper component may remain undiagnosed until it becomes symptomatic. Swelling, functional impairment, and limited joint motion occur when the child becomes older and more active, especially if playing sports. VM-LIC associated with large and intramuscular VM can manifest as early as the neonatal period.

Management

Due to the heterogeneity of VMs and the clinical and radiologic diagnostic overlap with other vascular anomalies, multidisciplinary management is recommended. VMs are reported to comprise up to 40% of referrals to vascular anomalies centers. VMs can be treated with many different modalities including sclerotherapy, excision, endovenous laser ablation, cutaneous laser ablation or a combination of these modalities. Sclerotherapy has emerged as the mainstay of treatment for VMs, followed by surgical excision. The decision regarding when to treat is usually based on whether there is significant functional impairment or disfigurement. Sclerotherapy involves the introduction of an endothelial-cell cidal sclerosant into the vascular spaces of the malformation.

Several different sclerosants can be used, including ethanol or sodium tetradecyl sulfate. Complications of sclerotherapy include tissue necrosis, nerve palsies, hemoglobinuria and oliguria. Surgical management can be most helpful in small or localized lesions. A combination of sclerotherapy followed by surgical debulking is often used in large or complex cases. In craniofacial lesions, therapy is aimed at preventing distortion of facial anatomy, limiting bone deformity, open bite or shift of the dental midline, lip expansion, and displacement of the lip commissures. MRI and ultrasound features may be especially helpful in determining optimal management. Multiple treatments are often required over years. Laser or radiofrequency ablation are occasionally helpful. Conservative therapy with compression should be initiated early on and is even encouraged from infancy in diffuse extremity VMs. Comp­ression increases comfort, limits swelling, and improves co­agulopathy. Compression is less useful for intramuscular VMs and may exacerbate pain.

Evaluation of large VMs includes assessment for, and possibly treatment of, VM-LIC. d -dimer levels should be obtained periodically to assess the extent of coagulopathy. Treatment with low-dose aspirin can be a helpful adjunct to conservative therapy in some cases. Low molecular weight heparin (LMWH) has been found to be useful in patients with chronic VM-LIC during episodes of exacerbation (thrombosis, pain) or before and after planned procedures such as sclerotherapy or surgical excision, to prevent thrombosis and/or control intraoperative hemorrhage. In patients with a history of thromboembolic events or in those with high risk, large and/or combined malformations, placement of an inferior or superior vena cava filter may help prevent pulmonary embolus.

Pathogenesis

The etiology of LMs is still unknown. LMs arise in a sporadic manner and no associated genetic basis has yet been discovered. This may suggest that a genetic cause is likely related to somatic mutations, which, if occurring within the germline, would be incompatible with life. This is in contrast to primary lymphedema, where several genetic mutations leading to specific lymphedema syndromes have been discovered and have improved our understanding of the molecular pathways involved in lymphangiogenesis. In primary lymphedema, defective lymphatic drainage leads to accumulation of lymphatic fluid in the interstitial space ( Fig. 22.7 ).

Congenital lymphedema.

(Courtesy of Angela Hernandez-Martin, MD.)

Several forms of lymphedema are known, including familial congenital lymphedema, Nonne–Milroy syndrome, Meige disease, and Hennekam syndrome, summarized in Table 22.3 .

Cutaneous findings

Macrocystic LMs are usually visible at birth and are commonly diagnosed by prenatal ultrasound investigation. They occur more commonly in the neck and axilla, where they are often referred to as cystic hygroma ( Fig. 22.8 ). The detection in utero of some huge LMs of the neck, axilla, and thoracic area may lead to a discussion about terminating the pregnancy, as the prognosis is poor. Microcystic LMs can infiltrate diffusely throughout the dermis. Clear or hemorrhagic vesicles (so-called ‘lymphangioma circumscriptum’), which may intermittently leak lymphatic fluid, may be visible on the surface of the lesion. Severe combined LMs may also occur on the trunk and limbs.

Large thoracic lymphatic malformation (‘cystic hygroma’) present at birth.

Extracutaneous findings

Cervicofacial LMs involving the tongue and floor of the mouth will interfere with normal development of the jaw and create an open bite deformity. The most severe forms of combined micro/macrocystic LMs, which are more common on the head and neck, can cause life-threatening airway disease and other functional problems in the neonate ( Fig. 22.9 ). Intraoral involvement also causes drainage of serosanguineous lymphatic fluid, aggressive caries, and loss of teeth. Involvement of the mandible with ensuing overgrowth is present in about 40% of these patients. Extra- and intraconal orbital LM occurs in association with eyelid LM; this uncommon location causes severe complications including disfigurement, bleeding, infection, proptosis, and visual loss. Severe cervicofacial LMs, usually the combined micro/macrocystic type, involving the hypopharynx and larynx, the tongue and the floor of the mouth, can cause airway and esophageal obstruction requiring nasogastric tube feeding and emergency tracheotomy in the newborn. Of 31 cases with such severe involvement, 58% required tracheostomy in infancy and one-third could not be decannulated. Visceral LMs, intrathoracic or abdominal, are less common, representing about one-tenth of cases. LMs are more susceptible to bacterial infections, and recurrent cellulitis can be a complication.

Large lymphatic malformation of the face with both microcystic and macrocystic elements involving the skin and mucosa.

Diagnosis

The diagnosis is established either clinically or using CT, MRI, or ultrasound. Fluid aspiration and analysis may be helpful because a number of neonatal growths, including some malignant tumors, can present with large cyst-like swellings. Histologically, lymphatic vessels or cysts have thin walls and lumina appear empty. Several positive immunohistochemical markers of lymphatic vessels have been identified, including LYVE-1, VEGFR-3 and D2-40, and can help to differentiate LM from other vascular anomalies.

Treatment

Lymphatic malformations are benign and treatment is usually directed at managing complications or attempting to restore anatomy. Conservative measures include observation, prophylactic antibiotics when infection is a concern, and in the case of primary lymphedema, compression. Sclerotherapy has emerged as an important treatment for LMs, and can be done early, even in the neonatal period. A variety of sclerosing agents have been used, including doxycycline, ethanol, bleomycin, OK-432 and STS. Macrocystic LMs respond very well to sclerotherapy. Surgical resection is another therapeutic option for macrocystic LMs, as well as for microcystic and combined types, but recurrences and complications such as seroma or chronic lymphatic leakage may occur. Radiofrequency ablation can be helpful in the management of LMs, most commonly for the lips and tongue to help decrease chronic leakage and bleeding.

A multidisciplinary approach is required for complex LMs.

Pathogenesis

Arteriovenous malformations arise due to errors in vascular development, which occur during embryogenesis. AVMs represent direct shunting from the arterial to the venous system due to the absence of an intervening capillary bed. Recently, the genetic basis for familial types of AVM has been discovered. Mutations in RASA1 have been found in individuals with AVM of the extremity (Parkes Weber syndrome) and in CM AVM syndrome (see below for further discussion on Parkes Weber syndrome), vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies caused by RASA1 mutations. Other mutations associated with AVMs or AVM variants include endoglin, which gives rise to hereditary hemorrhagic telangiectasia syndrome (HHT) and PTEN as seen in high flow lesions of the PTEN hamartoma tumor syndrome (see below).

Cutaneous findings

Most commonly, AVMs present as a pink vascular stain on the skin, mimicking port-wine stain. They are often located on the head and neck, the nose and central face/lip are common locations as is the ear ( Fig. 22.10 ). As mentioned above, lesions are warm and may have a thrill or a bruit. AVMs may develop pyogenic granulomas within them that bleed and may need to be excised or treated with laser ablation. Any patient who presents with small, multifocal lesions that resemble PWS but demonstrate high flow on Doppler examination should receive a workup for CM AVM syndrome (see below). Lesions may become thicker, more nodular and darker in color with time. AVMs often progress during puberty or with trauma.

(A) A 5-day-old neonate with a midfacial quiescent arteriovenous malformation that subsequently worsened and proved to be part of a Bonnet–Dechaume–Blanc syndrome. (B) The same child at 8 years of age.

Extracutaneous findings

AVMs can be life-threatening lesions that worsen over time. Complications include disfigurement, pain, bony erosion, hemorrhage, and even death. Large AVMs may have associated high-output heart failure at birth or later in life, requiring intervention.

Diagnosis

Most AVMs can be diagnosed based on their natural history and physical examination characteristics. They may not be obvious at birth, most commonly lesions mimic port-wine stain, but unlike PWS, AVMs expand through childhood. In general, AVMs are warm, a bruit may be audible, and a thrill may be palpable. An actual vascular mass with tense draining veins, a thrill, and a bruit is uncommon for AVM in a newborn, and may represent a congenital hemangioma (see Chapter 21 ). The Schobinger Classification of AVMs divides the presentation into four stages based on severity and associated findings: Stage I, lesions are quiescent; Stage II, AVMs have expanded and a thrill or bruit is palpable; Stage III, AVM destruction occurs and lesions can lead to ulceration, bleeding and pain; and Stage IV AVMs are associated with cardiac compromise.

Color Doppler ultrasonography as well as MR with MR angio­graphy may be helpful in diagnosis, as well as delineating the extent of disease. Angiography is sometimes done to aid in diagnosis or in preparation for embolization or resection. In contrast to VMs, AVMs are not known to be associated with LIC.

Management

Early on, conservative observation may be the best course for Stage I and II AVMs, as interventions may lead to enlargement or worsening of the lesions secondary to trauma. In more advanced malformations, where there are complications or functional compromise, embolization is usually the first-line treatment. Embolization can also be done prior to a planned surgical resection. Embolization involves the delivery of an embolic agent, usually ethanol, onyx, polyvinyl alcohol or coils, into the AVM in an attempt to block the blood flow and reduce shunting. Embolization is considered a palliative measure, as there is no cure for AVMs. Surgical management of AVMs should be performed with caution as exacerbation or recurrences are common and any resulting deformity may not be cosmetically acceptable.